Mabwell (Shanghai) Bioscience (HKG:2493, SHA:688062) obtained approval for a clinical trial of 6MW5311 for Injection from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.
The trial will test the drug for indications of hematological malignancies, including acute myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma.